The report documents how goods subject to higher U.S. tariffs are routinely rerouted through lower-tariff countries, undermining both tariff enforcement and American manufacturing.
For years, the de minimis loophole allowed foreign shippers to send packages valued at up to $800 into the United States duty-free, tax-free, and with virtually no customs scrutiny — so long as the foreign vendor merely alleged the value was below the threshold.
The companies that spent a year insisting tariffs were a tax on consumers are now cashing the refund checks themselves.
Today’s Section 232 proclamation secures that foundation, and the entire structure is built to reward one thing: manufacturing in America. Companies investing in U.S. polysilicon, wafer, and cell production are the clear winners, and companies that continue to rely on imports will be at a disadvantage.
Findings show that U.S. tariff policy leaves the aluminum industry’s largest employment base exposed, even as primary aluminum tariff costs are passed on to extruders and fabricators.
New CPA report finds America’s food security depends on fertilizer, and that foreign supply shocks—not U.S. trade remedies—are driving this year’s fertilizer crisis.
This report shows in stark numbers what American patients and pharmacists already feel every day – our medicine cabinet has been hollowed out, and we are now dangerously dependent on a handful of foreign, sometimes even adversarial, countries for the drugs that keep people alive.
President Trump’s revision to the steel tariff in 2025 was meant to fix the tariff inversion problem – situations where we tariff steel imports, but not things made of steel. Putting a tariff on metal can imports, but not metal cans filled with food, is a perfect example of mindless tariff inversion driving offshoring. This precise problem was solved and settled in 1930, and Commerce and USTR can fix it at any time with existing authority.
New duties on imports from dozens of countries take effect this week, closing the gap left after the Supreme Court struck down the President’s earlier tariff authority.
For years, the most critical link in our drug supply chain — the upstream chemistry — has been invisible to our own regulators. A medicine finished in Europe is not necessarily a European medicine, and this rule finally begins to expose that fiction.
